Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome

Bone Marrow Transplantation volume 25, pages 1041–1045 (2000)Cite this article

Abstract

Forty-five patients with metastatic breast cancer without clinically evident disease were treated with thiotepa 750 mg/m2, mitoxantrone 40 mg/m2 and carboplatin 1000 mg/m2 followed by stem cell transplantation to determine the safety and efficacy of CD34+ selection of peripheral blood stem cells. Of these, 15 patients’ (group I) stem cells were processed through Baxter Isolex 300 device for CD34+ selection, whereas 30 patients (group II) received unmanipulated stem cells. Toxicity, progression-free survival and survival were compared between these two groups. There was no difference in transfusion requirements, white cell count and platelet recovery and non-hematologic toxicity between the two groups. The survival of patients in group I was 27 months compared to 38 months in group II (P = 0.8). The progression-free survival was 12 months and 13.5 months for group I and group II patients, respectively (P = 0.6). Our results indicate that while there is no adverse effect, there is also no significant advantage of CD34+ selection in terms of progression-free survival and survival in patients with metastatic breast cancer without clinically evident disease. Bone Marrow Transplantation (2000) 25, 1041–1045.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Antman KH, Rowlings PA, Vaughan-WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879

    Article  CAS  Google Scholar 

  2. Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer Bone Marrow Transplant 1996 17: 769–774

    CAS  PubMed  Google Scholar 

  3. Cameron DA, Craig J, Gabra H et al. High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer – phase I/II study. Edinburgh Breast Group Br J Cancer 1996 74: 2013–2017

    Article  CAS  Google Scholar 

  4. Bezwoda WR, Seymour L, Dansey RD . High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial J Clin Oncol 1995 13: 2483–2489

    Article  CAS  Google Scholar 

  5. Laport GF, Grad G, Grinblatt DL et al. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10 year experience Bone Marrow Transplant 1998 21: 127–132

    Article  CAS  Google Scholar 

  6. Bensinger WI, Schiffman KS, Holmberg L et al. High dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer Bone Marrow Transplant 1997 19: 1183–1189

    Article  CAS  Google Scholar 

  7. Razis ED, Samonis G, Cook P et al. TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer J Med 1994 25: 241–250

    CAS  PubMed  Google Scholar 

  8. Brenner M . Gene marking Hum Gene Ther 1996 7: 1927–1936

    Article  CAS  Google Scholar 

  9. Moss TJ . Tumor contamination in stem cell products from patients with neuroblastoma and breast cancer Bone Marrow Transplant 1996 18: (Suppl 1) S17

    PubMed  Google Scholar 

  10. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest J Clin Oncol 1996 14: 214–219

    Article  CAS  Google Scholar 

  11. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques Blood 1993 182: 2605–2610

    Google Scholar 

  12. Farley TJ, Preti RA, Barton MK et al. The prognostic value of immunocytochemical testing for contaminating breast carcinoma cells: an analysis of infused stem cell products in patients with inflammatory and metastatic breast cancer J Clin Oncol (in press)

  13. Cooper BW, Moss TJ, Ross AA et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer J Clin Oncol 1998 16: 3509–3517

    Article  CAS  Google Scholar 

  14. Weaver CH, Moss T, Schwartzberg LS et al. High dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells Bone Marrow Transplant 1998 21: 1117–1124

    Article  CAS  Google Scholar 

  15. Saarinen UM, Coccia PF, Gerson SL et al. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow Cancer Res 1985 45: 5969–5975

    CAS  PubMed  Google Scholar 

  16. Ben Yosef R, Or R, Naparstek E et al. Should soybean agglutinin purging be performed in breast cancer patients undergoing autologous stem cell transplantation? A retrospective analysis of 48 patients Am J Clin Oncol 1997 20: 419–423

    Article  CAS  Google Scholar 

  17. Mapara MY, Korner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction Blood 1997 89: 337–344

    CAS  PubMed  Google Scholar 

  18. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment J Clin Oncol 1994 12: 28–36

    Article  CAS  Google Scholar 

  19. Farley TJ, Ahmed T, Fitzgerald M et al. Optimization of CD34+ cell selection using immunomagnetic beads: implications for use in cryopreserved peripheral blood stem cell collections J Hematother 1997 6: 53–60

    Article  CAS  Google Scholar 

  20. Stiff PJ, Koester AR, Weidner MK et al. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing Blood 1987 70: 974–978

    CAS  PubMed  Google Scholar 

  21. Ross AA, Loudovaris M, Hazelton B et al. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients Exp Hematol 1995 14: 1478–1483

    Google Scholar 

  22. Antman K, Ayash L, Elias A et al. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 1992 10: 102–110

    Article  CAS  Google Scholar 

  23. Gisselbrecht C, Extra JM, Lotz JP et al. Cyclophos-phamide/mitoxantrone/melphalan (CMA) prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer Bone Marrow Transplant 1996 18: 857–863

    CAS  PubMed  Google Scholar 

  24. Klump TR, Goldberg SL, Magdalinski AJ, Mangan KF . Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high risk non metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment Bone Marrow Transplant 1997 20: 273–281

    Article  Google Scholar 

  25. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 1988 6: 1368–1376

    Article  CAS  Google Scholar 

  26. Holland HK, Dix SP, Geller RB et al. Minimal toxicity and mortality in high risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem cell transplantation and comprehensive supportive care J Clin Oncol 1996 4: 1156–1164

    Article  Google Scholar 

  27. Kalacioglu ME, Lichtin AE, Andersen SW et al. High dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer Am J Oncol 1995 18: 491–494

    Article  Google Scholar 

  28. Vaughan WP, Reed EC, Edwards B et al. High dose cyclophosphamide, thiotepa, and hydroxyureas with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer Bone Marrow Transplant 1994 13: 619–624

    CAS  PubMed  Google Scholar 

  29. Todd NW, Peters WP, Ost AH et al. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation Am Rev Resp Dis 1993 147: 1264–1270

    Article  CAS  Google Scholar 

  30. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the ‘Philadelphia’ Intergroup Study (PBT-1) Proc ASCO 1999 18: 1a (Abstr. 1)

    Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Baxter Corporation. We thank Albert Hoang for statistical analysis. We also thank the nursing staff, physician assistants, and fellows for providing excellent care to our patients.

Author information

Authors and Affiliations

  1. Division of Oncology/Hematology, New York Medical College, Zalmen A Arlin Cancer Institute, Westchester Medical Center, Valhalla, NY, USA

    T Ahmed, R Kancherla, Z Qureshi, A Mittelman, K Seiter, A Mannancheril, C Puccio, HG Chun, M Lipshutz, MFaisal Ali, R Goldberg, D Lake & H Durrani

  2. Bennett Cancer Center, Stamford, CT, USA

    M Bar

  3. Clinical Services Division, New York Blood Center, Valhalla, NY, USA

    R Preti & T Farley

Authors
  1. T Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Kancherla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Mittelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Seiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Mannancheril
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Puccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. HG Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Bar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Lipshutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. MFaisal Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Preti
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Lake
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H Durrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. T Farley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahmed, T., Kancherla, R., Qureshi, Z. et al. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome. Bone Marrow Transplant 25, 1041–1045 (2000). https://doi.org/10.1038/sj.bmt.1702374

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702374

Keywords

This article is cited by

Search

Advanced search

Quick links